SM
ESPR

Scoggin Management’s Esperion Therapeutics ESPR Stock Holding History

Scoggin Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-25,000
Closed -$1.65M – 44
2017
Q4 		$1.65M Buy
+25,000
New +$1.35M 0.21% 41

Other funds holding ESPR

MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Scoggin Management's ESPR Position: Q1 2018 in Review

Scoggin Management sold out of Esperion Therapeutics (ESPR) in Q1 2018, closing a stake of 25,000 shares — an estimated $1.65M sold.

Scoggin Management first reported a position in ESPR in Q4 2017 and held it in 1 quarter. The position peaked at $1.65M in Q4 2017. 187 funds tracked by Wall St. Rank hold ESPR as of Q1 2018.

  • Scoggin Management reported no remaining Esperion Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Scoggin Management sold 25,000 Esperion Therapeutics shares in Q1 2018, an estimated $1.65M.
  • Scoggin Management first reported a position in Esperion Therapeutics in Q4 2017 and held it in 1 quarter.
  • Scoggin Management's Esperion Therapeutics position peaked at $1.65M in Q4 2017.
  • 187 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2018.

Based on Scoggin Management's 13F filing for Q1 2018, filed 15 May 2018.